XOLAIR (Omalizumab) Outcomes in Pediatric Allergic Asthma Patients in the United States

Completed

Conditions studied: Asthma

In brief

A retrospective database pre-post cohort study, identifying asthmatic patients, aged 6- 11, with omalizumab use over 24 months

Key facts

Study ID
NCT05157087
Run by
Novartis Pharmaceuticals
People needed
16246
Starts
2020-03-01
Expected to finish
2020-12-01
Last updated by the study team
2021-12-16

Who can join

Age: 6 and older, up to 11. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.